Industry
Bipartisan House Bill Proposes $35 Monthly Insulin Cap for Private Insurance
House lawmakers introduced bipartisan legislation Thursday to cap monthly insulin costs at $35 for people with private health insurance. The bill includes support from two battleground Republicans, marking a shift from previous GOP resistance to government price-setting. If enacted, the cap would affect privately insured patients; Medicaid beneficiaries already benefit from rebate protections and state-specific cost-sharing limits that often result in lower out-of-pocket costs. The legislation has been discussed for years but has not previously advanced due to concerns about government price controls.
Why it mattersPrivate insurance insulin pricing does not directly affect Medicaid programs, which already secure manufacturer rebates and typically limit cost-sharing for prescription drugs under different statutory frameworks.